文献速递慢性肾脏病

肾病进展临床试验新型分层复合终点的开发与验证

Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression.
PubMed 文献 · J Am Soc Nephrol · 2023-10-24

该研究基于七项安慰剂对照的3期临床试验(评估卡格列净、达格列净、非奈利酮、阿曲生坦、氯沙坦、厄贝沙坦和阿利吉仑)进行事后分析,开发并验证了一种结合临床肾脏结局与纵向GFR变化(GFR斜率)的分层复合终点(HCE)。在所有试验中,HCE的胜算比(WO)与原始主要肾脏结局的风险比(HR)在治疗效应方向上一致、幅度相似,且同等样本量下HCE可提高统计效能。

要点

  • HCE将全因死亡、肾衰竭、持续57%/50%/40%的GFR下降及GFR斜率按临床重要性分层组合。
  • 七项试验中,WO与HR反映的治疗效应方向一致、幅度相似。
  • 同等样本量下,采用HCE的临床试验比传统复合终点具有更高统计效能。

核心结论

  • 在七项大型肾脏临床试验中,WO与HR提供的治疗效应估计方向相似,较小的HR与较大的WO相关。
  • HCE优先考虑临床结局并纳入更广泛的复合终点,使其成为传统肾脏终点的有吸引力的替代选择。

研究设计与样本

  • 对七项评估卡格列净、达格列净、非奈利酮、阿曲生坦、氯沙坦、厄贝沙坦和阿利吉仑的3期安慰剂对照试验进行事后分析,开发并验证肾病进展的新型HCE。

主要发现

  • 在所有试验中,WO计算的疗效与HR相比反映相似的治疗效应方向和幅度。
  • 采用HCE的临床试验在同等样本量下比传统复合终点获得更高的统计效能。
  • 较小的HR与较大的WO相关。

关键数值与推荐

  • HCE定义为全因死亡、肾衰竭、持续57%、50%和40%的GFR下降及GFR斜率的分层复合终点。
  • WO描述活性药相比对照获得更有利结局的胜算。

临床怎么用

  • HCE可作为传统肾脏终点的替代,用于肾病进展临床试验,其优先临床结局并整合二分类与连续指标。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SIGNIFICANCE STATEMENT: The established composite kidney end point in clinical trials combines clinical events with sustained large changes in GFR but does not weigh the relative clinical importance of the end point components. By contrast, a hierarchical composite end point (HCE) accounts for the clinical importance of the end point components. The authors developed and validated a kidney HCE that combines clinical kidney outcomes with longitudinal GFR changes (GFR slope). They demonstrate that in seven major placebo-controlled kidney outcome trials with different medications, treatment effect estimates on the HCE were consistently in similar directions and of similar magnitudes compared with treatment effects on the established kidney end point. The HCE's prioritization of clinical outcomes and ability to combine dichotomous outcomes with GFR slope make it an attractive alternative to the established kidney end point. BACKGROUND: The established composite kidney end point in clinical trials combines clinical events with sustained large changes in GFR. However, the statistical method does not weigh the relative clinical importance of the end point components. A HCE accounts for the clinical importance of the end point components and enables combining dichotomous outcomes with continuous measures. METHODS: We developed and validated a new HCE for kidney disease progression, performing post hoc analyses of seven major Phase 3 placebo-controlled trials that assessed the effects of canagliflozin, dapagliflozin, finerenone, atrasentan, losartan, irbesartan, and aliskiren in patients with CKD. We calculated the win odds (WOs) for treatment effects on a kidney HCE, defined as a hierarchical composite of all-cause mortality; kidney failure; sustained 57%, 50%, and 40% GFR declines from baseline; and GFR slope. The WO describes the odds of a more favorable outcome for receiving the active compared with the control. We compared the WO with the hazard ratio (HR) of the primary kidney outcome of the original trials. RESULTS: In all trials, treatment effects calculated with the WO reflected a similar direction and magnitude of the treatment effect compared with the HR. Clinical trials incorporating the HCE would achieve increased statistical power compared with the established composite end point at equivalent sample sizes. CONCLUSIONS: In seven major kidney clinical trials, the WO and HR provided similar direction of treatment effect estimates with smaller HRs associated with larger WOs. The prioritization of clinical outcomes and inclusion of broader composite end points makes the HCE an attractive alternative to the established kidney end point.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Jongs N, Schloemer P, et al. Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression. J Am Soc Nephrol. 2023. PMID: 37872654. doi:10.1681/ASN.0000000000000243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。